[Correspondence] Why is survival after pembrolizumab affected by previous radiotherapy?

The secondary subgroup analysis of the single-centre KEYNOTE-001 phase 1 trial1 by Narek Shaverdian and colleagues, with the accompanying commentary by Dirk De Ruysscher on the association of previous radiotherapy and clinical activity of pembrolizumab in advanced non-small-cell lung cancer (NSCLC), is of great interest and clinical relevance. Progression-free survival and overall survival after pembrolizumab were significantly longer in patients who had received previous radiotherapy than in those who were radiotherapy naive.

http://ift.tt/2eMXE5F